CYTK
HealthcareCytokinetics, Incorporated
$61.26
$-0.47 (-0.76%)
Jan 5, 2026
Price History (1Y)
Analysis
Cytokinetics, Incorporated is a biotechnology company within the healthcare sector. With a market capitalization of $7.49B and 498 employees, it operates on a significant scale. The company's financial health is marked by substantial losses. The net income for the trailing twelve months (TTM) stands at -$751,944,000, while the EBITDA is -$563,284,992. The operating margin is -8613.4%, and the profit margin is 0.0%. Additionally, the return on assets is -24.9%. On the other hand, the company has a sizeable cash reserve of $962.53M but also carries debt worth $1.35B. The valuation context for Cytokinetics is characterized by an unfavorable P/E ratio of -10.45 and a price to sales ratio of 85.88. The revenue growth over the past year (YoY) has been substantial, at 318.1%. However, the earnings growth YoY is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $7.49B
- P/E Ratio
- N/A
- 52-Week High
- $70.98
- 52-Week Low
- $29.31
- Avg Volume
- 1.89M
- Beta
- 0.56
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 498